PP APCO/Lumiradx Related News
Driving change in healthcare using point-of-care diagnostics
In this special report, LumiraDx, a next generation point-of-care diagnostics platform, explores how point-of-care testing can support change in community-based healthcare, and alleviate the...
Adopt point-of-care diagnostics to cut carbon emissions, say over 80% of GPs
A new study by LumiraDX has found that the majority of the GP workforce believes that point-of-care diagnostics could cut carbon emissions.
Point-of-care diagnostics must...
LumiraDx continue rapid microfluidic immunoassay HbA1c test expansion
LumiraDx's rapid microfluidic immunoassay HbA1c test will now be available in Europe, parts of the Middle East, Asia, Latin America, and Africa.
Early customers...
Using point of care diabetes testing to improve treatment
LumiraDx’s new HbA1c test, run on the LumiraDx point of care platform, could dramatically improve patient management, and reduce healthcare costs associated with delays...
Diagnostic technology is central to tackling pandemics
“Supporting more widespread use of rapid diagnostic technology should be a central aim of efforts to tackle the next hidden pandemic” according to LumiraDx and the...
LumiraDx’s COVID-19 antigen test is the only test exceeding WHO’s desirable sensitivity target
In a Cochrane meta-analysis of 152 studies investigating over 100,000 nose and throat samples and 20 brands of COVID-19 tests, only the LumiraDx assay...
LumiraDx: Fighting antimicrobial resistance with innovative POC testing
Antimicrobial resistance (AMR) is ever-evolving and perhaps the most dangerous global health threat of modern times, an issue that will require cutting-edge innovation to...
LumiraDx C-reactive protein test accomplishes CE Marking
A cutting-edge, novel C-reactive protein test has successfully achieved CE Marking, a significant advancement in infection diagnostics.
Developed by LumiraDx, pioneering experts in the field...
